Establishment of Mesoporous Carbon Nano-drug Delivery System and Study on Its Chemotherapy-photo-therapy Combination for Anti-multidrug-resistant Tumor
10.6039/j.issn.1001-0408.2017.22.25
- VernacularTitle:介孔碳纳米粒的构建及化疗-光疗联合抗多药耐药肿瘤研究
- Author:
Fangzhou LI
;
Yanna YU
;
Hao ZHU
;
Yuanyuan SHEN
- Keywords:
Mesoporous carbon;
Nano-drug delivery system;
Photothermal therapy;
Photodynamic therapy;
Responsive;
Tu-mor multidrug resistance
- From:
China Pharmacy
2017;28(22):3117-3120
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To establish the mesoporous carbon nano-drug delivery system (MCNs) with chemotherapy drugs loaded and holding photothermal and photodynamic combined effect,and study its anti-multidrug-resistant tumor effect in vitro. METHODS:MCNs was prepared by low-concentration hydrothermal route,and the MCNs surface was carboxylated by the mixed acid ultrasound method to made MCNs-COOH (MCNC). The morphology and surface properties were evaluated. Adriamycinc (ADR)was loaded into MCNC to fabricate ADR/MCNC via adsorption method. Drug loading capacity was calculated by UV,and drug release profile was investigated by dialysis method. ADR-resistant human breast cancer MCF-7/ADR cells were chosen,and cell uptake and positioning of ADR/MCNC were observed by confocal laser microscopy;cytotoxicity of ADR/MCNC was detected by MTT method;and intracellular reactive oxygen species(ROS)level under NIR irradiation was measured by flow cytometry. RE-SULTS:The particle size of prepared MCNs was about 90 nm,with carboxyl in surface. The specific surface area was 541.62 m2/g,pore volume was 0.34 cm3/g,and pore size distribution was 2.5 nm,with significant photothermal effect. The drug loading ca-pacity of ADR/MCNC was 47.4%,showing pH/NIR responsiveness release characteristics. It can promote ADR in cell uptake and nuclear accumulation and induce MCF-7/ADR cell to generate ROS under NIR irradiation,with significant inhibitory effect. CON-CLUSIONS:MCNs is prepared successfully,and ADR/MCNC has an effect on anti-multidrug-resistant tumors.
